In some patients with well-differentiated thyroid carcinoma, dosimetry is necessary to avoid
toxicity from therapy and to guide prescription of the administered activity of radioiodine …

Radioiodine treatments of patients with well-differentiated thyroid carcinoma have generally
been safe and beneficial. Safety can be ensured while efficacy is increased through …

Nuclear Medicine Service and Medical Service, Hines Veterans Affairs Hospital, Hines,
Illinois; and Division of Nuclear Medicine, Department ofRadiology, and Department …

For almost five decades, 131I treatment of thyroid cancer has been based empirically on
administered activity rather than on actual radiation doses delivered. In 1983, we defined …

Ridioactive 131Ihas been used in he treatment of well-differenti ated thyroid carcinoma over
the past fifty years with general agreement from published reports of the safety and efficacy …

There is no consensus on the amount of 131I for treatment of patients with well-differentiated
thyroid carcinoma; usual amounts vary widely. Body retention of 131I has been shown to be …

The therapeutic response and survival rates of 352 patients with differentiated thyroid
carcinoma who had received radioactive iodine therapy since 1951 were studied. Of these …

Radioiodine has the distinction of being the first theranostic agent in our armamentarium.
Millennia were required to discover that the agent in orally administered seaweed and its …

A 150-mCi treatment dose of 131 I will result in a dose of 39,000 cGy to the thyroid and 36
cGy to the total body (1). Therefore, a discussion of side effects of 131 I therapy for thyroid …

Objectives This was a retrospective study to assess the efficacy and morbidity of high activity
131 I therapy in patients with advanced differentiated thyroid carcinoma. Methods From …